Drug intelligence / Profile preview

DWJ1506

Development stage: Phase 4
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules

Overview

DWJ1506 is a chemical compound under development by Daewoong Pharmaceutical for the treatment of dyslipidemia. It is being evaluated in phase 3 clinical trials to determine its efficacy and safety in patients with dyslipidemia. The precise mechanism of action and molecular target have not been disclosed publicly. Its development is focused within the therapeutic area of endocrinology and metabolic diseases, specifically targeting lipid disorders[1][2][3][6][7].

Brand names: Rovasro
Other names: DWJ 1506DWJ1506DWJ-1506

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on DWJ1506.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1506.

Explore the full profile